Success Metrics

Clinical Success Rate

91.7%

Based on 11 completed trials

Completion Rate

92%(11/12)

Active Trials

1(6%)

Results Posted

55%(6 trials)

Terminated

1(6%)

Phase Distribution

Ph phase_1

17%

Ph phase_2

22%

Ph phase_3

11%

Ph not_applicable

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution16 total trials

Phase 1Safety & dosage

3(18.8%)

Phase 2Efficacy & side effects

4(25.0%)

Phase 3Large-scale testing

2(12.5%)

Phase 4Post-market surveillance

6(37.5%)

N/ANon-phased studies

1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(11)

Terminated(2)

Other(4)

Detailed Status

Completed11

unknown4

Withdrawn1

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

91.7%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (18.8%)

Phase 24 (25.0%)

Phase 32 (12.5%)

Phase 46 (37.5%)

N/A1 (6.3%)

Trials by Status

withdrawn16%

recruiting16%

completed1161%

unknown422%

terminated16%

Recent Activity

1 active trials

Showing 5 of 18

completedphase_4

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

NCT05661552

completedphase_1

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

NCT06547359

terminatedphase_4

Clinical Trials (18)

Showing 18 of 18 trials

NCT05661552Phase 4

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Completed

NCT06547359Phase 1

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

Completed

NCT04638400Phase 4

Anti-inflammatory Effects of Simvastatin

Terminated

NCT04369664Phase 4

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Completed

NCT04701242Not Applicable

Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"

Recruiting

NCT05266586Phase 2

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Completed

NCT04770389Phase 2

Randomized Study of Obicetrapib in Combination With Ezetimibe

Completed

NCT05795517Phase 2

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

Completed

NCT05970679Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Completed

NCT05613400Phase 4

Statin and Bone Health

Unknown

NCT04589351Phase 3

Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe

Unknown

NCT05080140

Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

Unknown

NCT04895059Phase 1

Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components

Completed

NCT03051100Phase 2

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Completed

NCT03750760Phase 4

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Withdrawn

NCT03884127

Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.

Unknown

NCT02127320Phase 1

Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe

Completed

NCT00125593Phase 4

Study of Heart and Renal Protection

Completed

All 18 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 18